JP2019531745A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019531745A5 JP2019531745A5 JP2019520801A JP2019520801A JP2019531745A5 JP 2019531745 A5 JP2019531745 A5 JP 2019531745A5 JP 2019520801 A JP2019520801 A JP 2019520801A JP 2019520801 A JP2019520801 A JP 2019520801A JP 2019531745 A5 JP2019531745 A5 JP 2019531745A5
- Authority
- JP
- Japan
- Prior art keywords
- cmv
- mir
- vector
- nucleic acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000701022 Cytomegalovirus Species 0.000 claims 34
- 239000013598 vector Substances 0.000 claims 30
- 239000000427 antigen Substances 0.000 claims 19
- 102000036639 antigens Human genes 0.000 claims 17
- 108091007433 antigens Proteins 0.000 claims 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 12
- 150000007523 nucleic acids Chemical group 0.000 claims 12
- 108091008874 T cell receptors Proteins 0.000 claims 8
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 108700011259 MicroRNAs Proteins 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 239000002679 microRNA Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 108091023084 miR-126 stem-loop Proteins 0.000 claims 3
- 108091065272 miR-126-1 stem-loop Proteins 0.000 claims 3
- 108091081187 miR-126-2 stem-loop Proteins 0.000 claims 3
- 108091030790 miR-126-3 stem-loop Proteins 0.000 claims 3
- 108091092317 miR-126-4 stem-loop Proteins 0.000 claims 3
- 230000001717 pathogenic effect Effects 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 230000005867 T cell response Effects 0.000 claims 2
- 101150088910 UL82 gene Proteins 0.000 claims 2
- 101150085955 US11 gene Proteins 0.000 claims 2
- 210000003038 endothelium Anatomy 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- -1 miR-130a Proteins 0.000 claims 2
- 108091079658 miR-142-1 stem-loop Proteins 0.000 claims 2
- 108091071830 miR-142-2 stem-loop Proteins 0.000 claims 2
- 244000052769 pathogen Species 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 108010083359 Antigen Receptors Proteins 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 108091008875 B cell receptors Proteins 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 241000282693 Cercopithecidae Species 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000021309 Germ cell tumor Diseases 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- 241000282560 Macaca mulatta Species 0.000 claims 1
- 108091028080 MiR-132 Proteins 0.000 claims 1
- 108091033773 MiR-155 Proteins 0.000 claims 1
- 108091036422 MiR-296 Proteins 0.000 claims 1
- 108091028049 Mir-221 microRNA Proteins 0.000 claims 1
- 108091062140 Mir-223 Proteins 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 241001631646 Papillomaviridae Species 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 101150016730 UL79 gene Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 210000002798 bone marrow cell Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 108091064282 miR-125 stem-loop Proteins 0.000 claims 1
- 108091037066 miR-125-1 stem-loop Proteins 0.000 claims 1
- 108091062107 miR-125-2 stem-loop Proteins 0.000 claims 1
- 108091079767 miR-125-3 stem-loop Proteins 0.000 claims 1
- 108091032320 miR-146 stem-loop Proteins 0.000 claims 1
- 108091024530 miR-146a stem-loop Proteins 0.000 claims 1
- 108091062762 miR-21 stem-loop Proteins 0.000 claims 1
- 108091041631 miR-21-1 stem-loop Proteins 0.000 claims 1
- 108091044442 miR-21-2 stem-loop Proteins 0.000 claims 1
- 108091048308 miR-210 stem-loop Proteins 0.000 claims 1
- 108091061917 miR-221 stem-loop Proteins 0.000 claims 1
- 108091063489 miR-221-1 stem-loop Proteins 0.000 claims 1
- 108091055391 miR-221-2 stem-loop Proteins 0.000 claims 1
- 108091031076 miR-221-3 stem-loop Proteins 0.000 claims 1
- 108091029997 miR-328 stem-loop Proteins 0.000 claims 1
- 108091027983 miR-378-1 stem-loop Proteins 0.000 claims 1
- 108091089716 miR-378-2 stem-loop Proteins 0.000 claims 1
- 108091050734 miR-652 stem-loop Proteins 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022169043A JP7478794B2 (ja) | 2016-10-18 | 2022-10-21 | 主要組織適合遺伝子複合体ｅ分子によって拘束されるｔ細胞を誘発するサイトメガロウイルスベクター及びｈｃｍｖベクターを含む組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662409840P | 2016-10-18 | 2016-10-18 | |
| US62/409,840 | 2016-10-18 | ||
| PCT/US2017/057106 WO2018075591A1 (en) | 2016-10-18 | 2017-10-18 | Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022169043A Division JP7478794B2 (ja) | 2016-10-18 | 2022-10-21 | 主要組織適合遺伝子複合体ｅ分子によって拘束されるｔ細胞を誘発するサイトメガロウイルスベクター及びｈｃｍｖベクターを含む組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019531745A JP2019531745A (ja) | 2019-11-07 |
| JP2019531745A5 true JP2019531745A5 (enExample) | 2020-11-26 |
Family
ID=62018862
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520801A Pending JP2019531745A (ja) | 2016-10-18 | 2017-10-18 | 主要組織適合遺伝子複合体ｅ分子によって拘束されるｔ細胞を誘発するサイトメガロウイルスベクター |
| JP2022169043A Active JP7478794B2 (ja) | 2016-10-18 | 2022-10-21 | 主要組織適合遺伝子複合体ｅ分子によって拘束されるｔ細胞を誘発するサイトメガロウイルスベクター及びｈｃｍｖベクターを含む組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022169043A Active JP7478794B2 (ja) | 2016-10-18 | 2022-10-21 | 主要組織適合遺伝子複合体ｅ分子によって拘束されるｔ細胞を誘発するサイトメガロウイルスベクター及びｈｃｍｖベクターを含む組成物 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10532099B2 (enExample) |
| EP (1) | EP3529363B1 (enExample) |
| JP (2) | JP2019531745A (enExample) |
| KR (1) | KR102604486B1 (enExample) |
| CN (1) | CN110036112B (enExample) |
| AU (1) | AU2017346788A1 (enExample) |
| BR (1) | BR112019007982A2 (enExample) |
| CA (1) | CA3040303A1 (enExample) |
| CL (1) | CL2019001054A1 (enExample) |
| CO (1) | CO2019004102A2 (enExample) |
| CR (1) | CR20190205A (enExample) |
| DO (1) | DOP2019000086A (enExample) |
| EA (1) | EA201990937A1 (enExample) |
| EC (1) | ECSP19031754A (enExample) |
| IL (1) | IL266011B2 (enExample) |
| MA (1) | MA46588A (enExample) |
| MX (1) | MX2019004518A (enExample) |
| PE (1) | PE20190840A1 (enExample) |
| SG (1) | SG11201903340TA (enExample) |
| TN (1) | TN2019000124A1 (enExample) |
| UA (1) | UA126860C2 (enExample) |
| WO (1) | WO2018075591A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3351636T (pt) | 2010-05-14 | 2020-09-24 | Univ Oregon Health & Science | Vectores de hcmv e rhcmv recombinantes codificadores de um antigénio heterólogo isolado a partir de um vírus paramyxoviridae e seus usos |
| ES2667425T3 (es) | 2011-06-10 | 2018-05-10 | Oregon Health & Science University | Glucoproteínas y vectores recombinantes de CMV |
| LT2964769T (lt) | 2013-03-05 | 2018-12-10 | Oregon Health & Science University | Citomegalo viruso vektoriai, leidžiantys kontroliuoti ląstelių nukreipimą į taikinį |
| NZ728208A (en) | 2014-07-16 | 2018-07-27 | Univ Oregon Health & Science | Human cytomegalovirus comprising exogenous antigens |
| EA201791806A1 (ru) | 2015-02-10 | 2017-12-29 | Орегон Хелс Энд Сайенс Юниверсити | Способы и композиции, полезные при генерировании неканонических cd8+ т-клеточных ответов |
| US10688164B2 (en) | 2015-11-20 | 2020-06-23 | Oregon Health & Science University | CMV vectors comprising microRNA recognition elements |
| WO2018075591A1 (en) * | 2016-10-18 | 2018-04-26 | Oregon Health & Science University | Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules |
| US11077185B2 (en) | 2019-03-21 | 2021-08-03 | 21C Bio | Vaccine to pathogenic immune activation cells during infections |
| US10632186B1 (en) | 2019-03-21 | 2020-04-28 | 21C Bio | Vaccine to pathogenic immune activation cells during infections |
| WO2020188111A1 (en) | 2019-03-21 | 2020-09-24 | 21C Bio | Vaccine to pathogenic immune activation cells during infections |
| WO2020247859A2 (en) * | 2019-06-07 | 2020-12-10 | Oregon Health & Science University | Tumor-associated antigen-specific t cell responses |
| CN113950334B (zh) * | 2019-06-07 | 2025-01-28 | 俄勒冈健康与科学大学 | 乙型肝炎病毒特异性t细胞应答 |
| CA3148642A1 (en) * | 2019-08-20 | 2021-02-25 | Klaus J. FRUEH | Modulation of t cell responses by ul18 of human cytomegalovirus |
| BR112022003474A2 (pt) | 2019-08-29 | 2022-05-24 | Triad Nat Security Llc | Vacinas do vírus da hepatite b |
| JP2023507142A (ja) * | 2019-12-16 | 2023-02-21 | オレゴン ヘルス アンド サイエンス ユニバーシティ | 多重特異性ｔ細胞受容体 |
| KR20240049802A (ko) | 2021-08-31 | 2024-04-17 | 비르 바이오테크놀로지, 인코포레이티드 | 결핵 백신 |
| CN117836311A (zh) * | 2021-08-31 | 2024-04-05 | 维尔生物科技公司 | 用于产生cmv载体的方法 |
| US20240384296A1 (en) * | 2021-08-31 | 2024-11-21 | Vir Biotechnology, Inc. | Recombinant hcmv vectors and uses thereof |
| WO2024121424A1 (en) | 2022-12-09 | 2024-06-13 | Daniel Zagury | Composite aids vaccine generating anti-hiv specific neutralizing antibodies and/or anti-hiv cytotoxic t cells |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5273876A (en) | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
| CA1327171C (en) | 1987-06-26 | 1994-02-22 | Lisa J. Hock | Recombinant human cytomegalovirus containing foreign gene and use thereof |
| SG49046A1 (en) | 1991-07-05 | 1998-05-18 | American Cyanamid Co | Method for identifying non-essential genes of the human cytomegalovirus genome and for screening for inhibitors of human cytomegaloverirus |
| WO1995003399A2 (en) | 1993-07-19 | 1995-02-02 | Cantab Pharmaceuticals Research Limited | Production method for preparation of disabled viruses |
| US5833993A (en) | 1994-04-29 | 1998-11-10 | Pharmacia & Upjohn Company | Feline immunodeficiency virus vaccine |
| US5846806A (en) | 1994-07-29 | 1998-12-08 | American Cyanamid Company | Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression |
| ES2264136T3 (es) | 1995-02-21 | 2006-12-16 | Cantab Pharmaceuticals Research Limited | Preparaciones virales, vectores, inmunogenos y sus vacunas. |
| WO1996031241A1 (en) | 1995-04-04 | 1996-10-10 | Cell Genesys, Inc. | Transplantation of genetically modified cells having low levels of class i mhc proteins on the cell surface |
| WO1998004285A1 (en) | 1996-07-31 | 1998-02-05 | Ortho Pharmaceutical Corporation | Identification of human cytomegalovirus genes involved in down-regulation of mhc class i heavy chain expression |
| US20030138454A1 (en) | 1997-06-09 | 2003-07-24 | Oxxon Pharmaccines, Ltd. | Vaccination method |
| DE19733364A1 (de) | 1997-08-01 | 1999-02-04 | Koszinowski Ulrich H Prof | Verfahren zur Klonierung eines großen Virusgenoms |
| WO1999007869A1 (en) | 1997-08-05 | 1999-02-18 | University Of Florida | Live recombinant vaccine comprising inefficiently or non-replicating virus |
| US7204990B1 (en) | 2000-11-28 | 2007-04-17 | Medimmune Vaccines, Inc. | Attenuation of cytomegalovirus virulence |
| CA2437201C (en) | 2001-02-02 | 2008-11-18 | Chemocentryx, Inc. | Methods and compositions useful for stimulating an immune response |
| WO2002066629A2 (en) | 2001-02-21 | 2002-08-29 | Gabriele Hahn | Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates |
| GB0122232D0 (en) | 2001-09-14 | 2001-11-07 | Medical Res Council | Gene expression |
| JP4601956B2 (ja) | 2001-09-20 | 2010-12-22 | グラクソ グループ リミテッド | Ｈｉｖ−ｇａｇのコドン最適化ｄｎａワクチン |
| US20030118568A1 (en) | 2001-12-18 | 2003-06-26 | Board Of Trustees Of The University Of Arkansas | Viral stealth technology to prevent T cell-mediated rejection of xenografts |
| EP1497412A4 (en) | 2002-04-30 | 2006-11-22 | Avior Therapeutics Inc | ADENOVIRUS VECTORS USED IN IMMUNOTHERAPY |
| DE10232322A1 (de) * | 2002-07-16 | 2004-07-29 | Hahn, Gabriele, Dr. | Viral kodierte CxC determinieren den Gewebetropismus von HCMV |
| US7407744B2 (en) | 2003-07-25 | 2008-08-05 | The Regents Of The University Of California | Cytomegalovirus gene function and methods for developing antivirals, anti-CMV vaccines, and CMV-based vectors |
| AU2005285513B2 (en) | 2004-05-25 | 2011-02-24 | Oregon Health And Science University | SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors |
| EP1602676A1 (en) | 2004-06-01 | 2005-12-07 | SOLVAY (Société Anonyme) | Catalytic compositions |
| WO2006004661A1 (en) | 2004-06-25 | 2006-01-12 | Medimmune Vaccines, Inc. | Recombinant human cytomegalovirus and vaccines comprising heterologous antigens |
| WO2006125983A1 (en) | 2005-05-23 | 2006-11-30 | Oxxon Therapeutics Ltd | Compositions for inducing an immune response against hepatitis b |
| US8765146B2 (en) | 2005-08-31 | 2014-07-01 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
| WO2008112146A2 (en) | 2007-03-07 | 2008-09-18 | The Trustees Of The University Of Pennsylvania | 2d partially parallel imaging with k-space surrounding neighbors based data reconstruction |
| WO2009023386A2 (en) | 2007-07-06 | 2009-02-19 | Trubion Pharmaceuticals, Inc. | Binding peptides having a c-terminally disposed specific binding domain |
| HUE024877T2 (en) | 2007-10-30 | 2016-02-29 | Genentech Inc | Antibody purification by cation exchange chromatography |
| US8883995B2 (en) | 2009-03-06 | 2014-11-11 | Icahn School Of Medicine At Mount Sinai | Live attenuated influenza virus vaccines comprising microRNA response elements |
| MX2011011508A (es) * | 2009-04-30 | 2012-02-13 | San Raffaele Centro Fond | Vector genico. |
| AU2010334809C1 (en) | 2009-12-23 | 2015-02-26 | Agenus Inc. | Binding members for human cytomegalovirus |
| US20120289760A1 (en) | 2010-01-27 | 2012-11-15 | Hill Ann B | Cytomegalovirus-based immunogenic preparations |
| WO2011119920A2 (en) | 2010-03-25 | 2011-09-29 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| JP2013527758A (ja) | 2010-05-05 | 2013-07-04 | ティリオン，クリスティアン | ベータヘルペスウイルス感染に対するワクチンおよびその使用 |
| PT3351636T (pt) * | 2010-05-14 | 2020-09-24 | Univ Oregon Health & Science | Vectores de hcmv e rhcmv recombinantes codificadores de um antigénio heterólogo isolado a partir de um vírus paramyxoviridae e seus usos |
| ES2667425T3 (es) | 2011-06-10 | 2018-05-10 | Oregon Health & Science University | Glucoproteínas y vectores recombinantes de CMV |
| WO2013040320A1 (en) | 2011-09-16 | 2013-03-21 | Oregon Health & Science University | Methods and kits used in identifying microrna targets |
| US20130156808A1 (en) | 2011-11-22 | 2013-06-20 | Stipan Jonjic | Vaccine comprising beta-herpesvirus |
| EP2929034A4 (en) | 2012-12-04 | 2016-06-22 | Merck Sharp & Dohme | VIRUS VECTORS WITH CONDITIONAL REPLICATION |
| LT2964769T (lt) | 2013-03-05 | 2018-12-10 | Oregon Health & Science University | Citomegalo viruso vektoriai, leidžiantys kontroliuoti ląstelių nukreipimą į taikinį |
| NZ728208A (en) * | 2014-07-16 | 2018-07-27 | Univ Oregon Health & Science | Human cytomegalovirus comprising exogenous antigens |
| EP3048114A1 (en) | 2015-01-22 | 2016-07-27 | Novartis AG | Cytomegalovirus antigens and uses thereof |
| EA201791806A1 (ru) | 2015-02-10 | 2017-12-29 | Орегон Хелс Энд Сайенс Юниверсити | Способы и композиции, полезные при генерировании неканонических cd8+ т-клеточных ответов |
| US10688164B2 (en) | 2015-11-20 | 2020-06-23 | Oregon Health & Science University | CMV vectors comprising microRNA recognition elements |
| AU2017280065B2 (en) * | 2016-06-22 | 2021-07-01 | International Aids Vaccine Initiative, Inc. | Recombinant cytomegalovirus vectors as vaccines for tuberculosis |
| US20200182884A1 (en) | 2016-06-27 | 2020-06-11 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
| WO2018075591A1 (en) * | 2016-10-18 | 2018-04-26 | Oregon Health & Science University | Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules |
-
2017
- 2017-10-18 WO PCT/US2017/057106 patent/WO2018075591A1/en not_active Ceased
- 2017-10-18 PE PE2019000824A patent/PE20190840A1/es unknown
- 2017-10-18 CR CR20190205A patent/CR20190205A/es unknown
- 2017-10-18 MX MX2019004518A patent/MX2019004518A/es unknown
- 2017-10-18 CN CN201780064422.7A patent/CN110036112B/zh active Active
- 2017-10-18 TN TNP/2019/000124A patent/TN2019000124A1/en unknown
- 2017-10-18 UA UAA201904893A patent/UA126860C2/uk unknown
- 2017-10-18 BR BR112019007982A patent/BR112019007982A2/pt not_active Application Discontinuation
- 2017-10-18 CA CA3040303A patent/CA3040303A1/en active Pending
- 2017-10-18 EP EP17862978.8A patent/EP3529363B1/en active Active
- 2017-10-18 US US15/786,847 patent/US10532099B2/en active Active
- 2017-10-18 SG SG11201903340TA patent/SG11201903340TA/en unknown
- 2017-10-18 JP JP2019520801A patent/JP2019531745A/ja active Pending
- 2017-10-18 IL IL266011A patent/IL266011B2/en unknown
- 2017-10-18 KR KR1020197013148A patent/KR102604486B1/ko active Active
- 2017-10-18 MA MA046588A patent/MA46588A/fr unknown
- 2017-10-18 EA EA201990937A patent/EA201990937A1/ru unknown
- 2017-10-18 AU AU2017346788A patent/AU2017346788A1/en not_active Abandoned
-
2019
- 2019-04-08 DO DO2019000086A patent/DOP2019000086A/es unknown
- 2019-04-17 CL CL2019001054A patent/CL2019001054A1/es unknown
- 2019-04-24 CO CONC2019/0004102A patent/CO2019004102A2/es unknown
- 2019-05-07 EC ECSENADI201931754A patent/ECSP19031754A/es unknown
- 2019-11-26 US US16/696,403 patent/US11305015B2/en active Active
-
2022
- 2022-10-21 JP JP2022169043A patent/JP7478794B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019502371A5 (enExample) | ||
| Zhou et al. | Cancer vaccines: current status and future directions | |
| Zeng et al. | Exhausted T cells and epigenetic status | |
| EP3947682B1 (en) | Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir) | |
| Obar et al. | Endogenous naive CD8+ T cell precursor frequency regulates primary and memory responses to infection | |
| Xiao et al. | CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy | |
| JP2018509148A5 (enExample) | ||
| JP2022518463A5 (enExample) | ||
| JP2019176869A5 (enExample) | ||
| Nishimura et al. | Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation | |
| Suehiro et al. | Clinical outcomes of a novel therapeutic vaccine with Tax peptide‐pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study | |
| CN104087592B (zh) | Afp158-166特异性tcr基因及其转基因t细胞及体外增殖方法及用途 | |
| KR102604486B1 (ko) | 주요 조직적합성 복합체 분자에 의해 제한된 t 세포를 유발하는 사이토메갈로바이러스 벡터 | |
| JP2017508468A5 (enExample) | ||
| van de Wall et al. | Potent therapeutic efficacy of an alphavirus replicon DNA vaccine expressing human papilloma virus E6 and E7 antigens | |
| Nishimura et al. | Cancer immunotherapy using novel tumor‐associated antigenic peptides identified by genome‐wide cDNA microarray analyses | |
| Ryan | microRNAs in cancer susceptibility | |
| JP2017522312A5 (enExample) | ||
| Sundarasetty et al. | Lentivirus-induced ‘Smart’dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma | |
| Harland et al. | Epigenetic plasticity of Cd8a locus during CD8+ T-cell development and effector differentiation and reprogramming | |
| JP2019508044A5 (enExample) | ||
| CN112867501A (zh) | 新的癌抗原和方法 | |
| CN114206913A (zh) | 新的癌抗原和方法 | |
| Mossoba et al. | Cancer immunotherapy using virally transduced dendritic cells: animal studies and human clinical trials | |
| JP2022502062A5 (enExample) |